KMT2A and acute lymphoblastic leukemia: Despite highly intensified treatment protocols, event‐free survival (EFS) chances for MLL‐rearranged infant ALL only reach 35‐40%, falling well short of survival rates of infants and older children with ALL carrying other cytogenetic aberrations (70‐90%) [1, 2, 3].